These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 2743343

  • 1. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL, Brown TD, Kuhn JG, Shen HS, O'Rourke TJ, Beougher K, Brentzel HJ, Von Hoff DD, Weiss GR.
    Cancer Res; 1989 Aug 15; 49(16):4648-53. PubMed ID: 2743343
    [Abstract] [Full Text] [Related]

  • 2. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
    Noe DA, Rowinsky EK, Shen HS, Clarke BV, Grochow LB, McGuire WB, Hantel A, Adams DB, Abeloff MD, Ettinger DS.
    Cancer Res; 1990 Aug 01; 50(15):4595-9. PubMed ID: 2369734
    [Abstract] [Full Text] [Related]

  • 3. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW.
    Clin Cancer Res; 2003 Nov 01; 9(14):5178-86. PubMed ID: 14613997
    [Abstract] [Full Text] [Related]

  • 4. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG, Balcerzak SP, Kraut EH.
    Cancer Res; 1993 Oct 15; 53(20):4843-9. PubMed ID: 8402671
    [Abstract] [Full Text] [Related]

  • 5. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
    Vogelzang NJ, Mick R, Janisch L, Berezin F, Schilsky RL, Ratain MJ.
    Cancer Res; 1994 Jan 01; 54(1):114-9. PubMed ID: 8261430
    [Abstract] [Full Text] [Related]

  • 6. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
    Peters GJ, Schwartsmann G, Nadal JC, Laurensse EJ, van Groeningen CJ, van der Vijgh WJ, Pinedo HM.
    Cancer Res; 1990 Aug 01; 50(15):4644-9. PubMed ID: 2164443
    [Abstract] [Full Text] [Related]

  • 7. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
    Egorin MJ, Sigman LM, Van Echo DA, Forrest A, Whitacre MY, Aisner J.
    Cancer Res; 1987 Jan 15; 47(2):617-23. PubMed ID: 3791246
    [Abstract] [Full Text] [Related]

  • 8. Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule.
    O'Dwyer PJ, Hudes GR, Walczak J, Schilder R, LaCreta F, Rogers B, Cohen I, Kowal C, Whitfield L, Boyd RA.
    Cancer Res; 1992 Dec 15; 52(24):6746-53. PubMed ID: 1458462
    [Abstract] [Full Text] [Related]

  • 9. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

  • 10. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1998 May 15; 4(5):1153-8. PubMed ID: 9607572
    [Abstract] [Full Text] [Related]

  • 11. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I, Bench K, Beijnen JH, Bruntsch U, Cavalli F, de Jong J, Groot Y, van Tellingen O, Wanders J, Sessa C.
    Clin Cancer Res; 1996 Oct 15; 2(10):1717-23. PubMed ID: 9816122
    [Abstract] [Full Text] [Related]

  • 12. Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule.
    Harman GS, Craig JB, Kuhn JG, Luther JS, Turner JN, Weiss GR, Tweedy DA, Koeller J, Tuttle RL, Lucas VS.
    Cancer Res; 1988 Aug 15; 48(16):4706-10. PubMed ID: 3396016
    [Abstract] [Full Text] [Related]

  • 13. Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule.
    Von Hoff DD, Kuhn JG, Havlin KA, Langevin AM, Brown TD, Weiss GR, Turner JN, Purvis J, Lucas VS, Bair KW.
    Cancer Res; 1990 Dec 01; 50(23):7496-500. PubMed ID: 2253197
    [Abstract] [Full Text] [Related]

  • 14. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
    Pitot HC, McElroy EA, Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL, Rubin J, Goldberg RM, Adjei AA, Ames MM.
    Clin Cancer Res; 1999 Mar 01; 5(3):525-31. PubMed ID: 10100703
    [Abstract] [Full Text] [Related]

  • 15. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Kojima A, Saijo N.
    Cancer Res; 1991 Mar 01; 51(5):1472-7. PubMed ID: 1997185
    [Abstract] [Full Text] [Related]

  • 16. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
    Schilder RJ, LaCreta FP, Perez RP, Johnson SW, Brennan JM, Rogatko A, Nash S, McAleer C, Hamilton TC, Roby D.
    Cancer Res; 1994 Feb 01; 54(3):709-17. PubMed ID: 8306332
    [Abstract] [Full Text] [Related]

  • 17. A phase I clinical and pharmacokinetic trial of hepsulfam.
    Ravdin PM, Havlin KA, Marshall MV, Brown TD, Koeller JM, Kuhn JG, Rodriguez G, Von Hoff DD.
    Cancer Res; 1991 Dec 01; 51(23 Pt 1):6268-72. PubMed ID: 1933887
    [Abstract] [Full Text] [Related]

  • 18. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F, Culine S, Bressolle F, Astre C, Serre MP, Chevillard C, Fabbro M.
    Clin Cancer Res; 2000 Jan 01; 6(1):57-63. PubMed ID: 10656432
    [Abstract] [Full Text] [Related]

  • 19. Phase I clinical and pharmacological study of merbarone.
    Dimaggio JJ, Warrell RP, Muindi J, Stevens YW, Lee SJ, Lowenthal DA, Haines I, Walsh TD, Baltzer L, Yaldaei S.
    Cancer Res; 1990 Feb 15; 50(4):1151-5. PubMed ID: 2297763
    [Abstract] [Full Text] [Related]

  • 20. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.
    Cancer J Sci Am; 1997 Feb 15; 3(5):297-302. PubMed ID: 9327154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.